Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM
Carmot begins Phase 2 trial of dual GLP-1/GIP RA CT-868 for the treatment of type 1 diabetes
People with obesity burn less energy during day
Journal Watch 15/11/2023
Updates on banded procedure studies and randomised controlled trials
SELECT: Semaglutide reduces CV events in non-diabetic patients with overweight or obesity